Objective: Long-term progression of peripheral arterial disease (PAD) as initial manifestation of atherosclerotic arterial disease is not well described. Cardiovascular (CV) risk was examined in different PAD populations diagnosed in a hospital setting in Sweden.
in age demographics, societies will face profound medical, social, and economic challenges associated with the care of patients with atherosclerotic disease.
Patients with symptomatic PAD are at high risk of cardiovascular (CV) events and premature death owing to the polyvascular nature of atherosclerosis. 4 Data indicate even higher rates of CV death in patients with PAD than in patients with coronary heart disease (CHD) or cerebrovascular disease. 5 Furthermore, a recent Danish nationwide study demonstrated a greater longterm risk of both total and CV-related death for patients with incident PAD than for those with incident myocardial infarction (MI), for both women and men. 6 Such real-world data support the consideration of PAD as a CHD risk equivalent and imply that similar preventive measures should be offered to both patients with CHD and those with PAD. 7 In reality, systemic vascular events may not be optimally treated in patients with PAD. 8, 9 Current recommendations for PAD include regular antiplatelet therapy and as-needed treatment with statins and antihypertensive drugs to achieve target values for serum lipids and blood pressure, respectively. 7, 10, 11 Knowledge of drug therapy use in large, unselected PAD populations is scarce and the impact of atherosclerotic manifestations is not well understood. 12 The aim of this study was to describe CV risk and secondary prevention drug therapy patterns from a nationwide perspective in patients with incident PAD as the initial atherosclerotic diagnosis compared with individuals in whom PAD was a subsequent diagnosis following CHD or ischemic stroke (IS).
METHODS
Study design. Data for this observational study were retrieved by linking data from Swedish mandatory national registers: the Swedish National Patient Register (NPR; inpatient admission and discharge dates and main and secondary diagnoses according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision ), the Swedish Prescribed Drug Register, and the Swedish Cause of Death Register. The Swedish NPR covers >99% of all somatic (including surgery) and psychiatric hospital discharges. 13 The Swedish Prescribed Drug Register contains data on all prescribed medications dispensed from pharmacies in Sweden.
14 By using the unique personal number for every citizen in Sweden, patient-level data from the registers were linked together and thereafter replaced by a study identification in the further processing of data. The regional ethics committee at the University of Gothenburg, Sweden, approved the study protocol (reference No. 649-14). Individual patient informed consent is not required for register studies in Sweden. The Swedish National Board of Health and Welfare approved and performed the linkage of data, and the Institute of Medicine at the Sahlgrenska Academy, Gothenburg, Sweden managed the database.
Study populations. All patients with incident primary or secondary PAD (ICD-10 codes I70.0 [atherosclerosis of aorta], I70.2 [atherosclerosis of arteries of extremities], and I73.9 [peripheral vascular disease, unspecified]) diagnosed in a hospital setting (both inpatient and outpatient settings) between 2006 and 2013 were included. The date of the first recorded PAD diagnosis during the specified study period was the index date for each patient. The PAD diagnosis in a hospital setting in Sweden is normally based on medical history and results from a clinical vascular examination including the ankle-brachial index test. Patients diagnosed with PAD in a hospital setting before the study period were excluded.
Four study populations were defined on the basis of the patients' clinical status when receiving their first PAD diagnosis (Appendix, online only).
1. Primary PAD: patients with PAD without any previous diagnosis of CHD (defined as a history of MI, unstable angina pectoris, angina pectoris) or IS 2. PAD þ CHD: patients with PAD and a previous diagnosis of CHD but without IS 3. PAD þ IS: patients with PAD and a previous diagnosis of IS but without CHD 4. PAD þ IS þ CHD: patients with PAD and a previous diagnosis of both IS and CHD Data for comorbidities and drug use at baseline were retrieved from national registers.
Drug treatment and adherence. Drug therapy at hospital discharge for the index PAD diagnosis included use of dispensed drugs from pharmacies 6 months before and until 30 days after the index PAD diagnosis. Drug adherence was described as the proportion of patients receiving the specific drug each day from 12 months before the date of PAD diagnosis until 12 months after. Drug adherence was based on calculations of the number of pills dispensed and the estimated number of pills taken each day.
Outcomes. The primary CV end point was a composite of hospitalization with main diagnosis of nonfatal MI (ICD-10 code I21), nonfatal IS (ICD-10 codes I63-I64), or CV death (death with ICD-10 codes I00-I99) as a primary diagnosis. Lower limb revascularization was defined as an open or endovascular procedure and registered in the inpatient register with operations codes (Appendix, online only). Recommendation: The authors suggest that risk prevention should be a key strategy in managing patients with PAD to reduce CV events and death. categorical variables. Each patient was observed from date of index diagnosis to date of death or end of study observational period (December 31, 2013). The primary composite end point was determined, and KaplanMeier analysis was used to estimate the proportion of patients with end point during the observational period. If one patient had several events, only the first was used in the survival model. Separate analyses were performed for the individual outcomes of the composite end point. Furthermore, time to all-cause death was analyzed separately. A Cox proportional hazards model was used to compare the outcome in the four study populations adjusted for prespecified CV risk factors (age, sex, heart failure, atrial fibrillation, and diabetes mellitus). Results are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.2.3.
RESULTS
Study population. Of the 141,266 patients with a diagnosis of PAD identified in the Swedish NPR, 66,189 (total PAD study population) remained after exclusion of patients in whom PAD was diagnosed before the study period. Of these, 40,136 were included in the primary PAD population, 16,786 in the PAD þ CHD population, 5803 in the PAD þ IS population, and 3464 in the multivessel (PAD þ IS þ CHD) population. Patients were observed for a mean of 2.8 years, with a maximum follow-up of 8 years, comprising a total follow-up of 184,614 patient-years.
Primary PAD and PAD as part of multivessel disease were mainly diagnosed at hospital outpatient visits (76% and 64%, respectively). Furthermore, 91% (primary PAD) and 89% (multivessel disease) of all incident PAD diagnoses set during hospital outpatient visits were primary diagnoses (the main reason for hospital contact).
The primary PAD population was younger and included more women (51.6% vs 48.4% men) than the other populations (Table I ). The prevalence of diabetes mellitus, chronic renal insufficiency, and chronic obstructive pulmonary disease in the primary PAD population was 25%, 2.7%, and 8%; in the PAD þ CHD population, it was 38%, 4.8%, and 12%; and in the PAD þ IS population, it was 35%, 3.4%, and 7%, respectively. Patients with multivessel disease were more commonly men and had an even higher prevalence of comorbidities than the other three populations (Table I) . Primary PAD and multivessel disease were mainly diagnosed at hospital outpatient visits (76% and 64%, respectively).
Secondary prevention drug therapy and adherence to treatment. Overall, compared with the other populations of patients, a lower proportion of the primary PAD population received guideline-recommended therapies at discharge, whereas the PAD þ CHD population was most intensively treated with secondary prevention drug therapy. For example, antiplatelet therapy and statins were used by 62% and 48% of the primary PAD population, 82% and 68% of the PAD þ CHD population, 76% and 46% of the PAD þ IS population, and 80% and 61% of the PAD þ IS þ CHD population, respectively (Table I) .
The primary PAD population showed the most pronounced change in drug therapy of the four populations of patients following PAD diagnosis. The proportion of patients receiving low-dose acetylsalicylic acid increased from 38% 1 week before diagnosis to 57% 3 months after, and the proportion of patients receiving statins increased from 29% to 46%. Only a small proportion of patients with primary PAD (<10%) were treated with clopidogrel. There were no substantial changes in the proportions of patients receiving beta blockers or angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor blockers following PAD diagnosis (Fig 1) .
Risk of CV outcomes and all-cause death. After 1 year of follow-up, the cumulative incidence rate of the major CV composite end point MI, IS, or CV death for the whole study population was 16.6%. The corresponding number for all-cause death was 21.1%. Of the patients who had a major CV event during the first year after PAD diagnosis, 14.9% had a nonfatal MI, 12.2% had a nonfatal IS, and 72.9% died with cause of death related to CV causes. In addition, 8.3% of all patients died of non-CV causes.
The 1-year cumulative incidence rates of the primary composite major CV events in primary PAD, PAD þ CHD, PAD þ IS, and PAD þ IS þ CHD were 12%, 21%, 29%, and 34%, respectively (Fig 2) ; the corresponding numbers for all-cause death were 16%, 22%, 33%, and 35% (Fig 3) . Compared with the primary PAD population, the relative risk increase for a major CV event after adjustment for baseline covariates (age, sex, heart failure, atrial fibrillation, and diabetes mellitus) was highest in the PAD þ IS þ CHD population (HR, 2.01), followed by PAD þ IS (HR, 1.87) and PAD þ CHD (HR, 1.42; all comparisons P < .001; Table II) . Compared with the primary PAD population, the relative risk increase for all-cause death after adjustment for baseline covariates was highest in the PAD þ IS population (HR, 1.50) and PAD þ IS þ CHD population (HR, 1.32; both comparisons P < .001; Table II ). A history of CHD when diagnosed with PAD did not increase the all-cause death risk (HR, 0.98; 95% CI, 0.95-1.01; P ¼ .197).
Performed procedures. In total, 23,481 lower limb revascularization procedures were performed during the study period for the included patients. The cumulative incidence rate of lower limb revascularization procedures for the whole study population was 20.1 (95% CI, 19.8-20.4) at 6 months and 23.2 (95% CI, 22.9-23.5) at 1 year. No major differences in proportion of patients undergoing revascularization procedures were observed between the study populations (Supplementary  Tables I and II, online only) .
DISCUSSION
In this nationwide cohort study, more than one patient in five diagnosed with PAD in a hospital setting will die within 1 year, and one in six will experience a major CV event within a year. The majority of PAD diagnoses were set as primary diagnosis at hospital outpatient visits, meaning that these patients were referred from primary care on the basis of symptoms indicating PAD. Patients with symptomatic PAD as the initial manifestation of atherosclerotic disease are at high risk of subsequent CV events: one in six patients will die and one in eight will experience a major CV event within 1 year. Many patients in the primary PAD population did not receive guideline-recommended secondary preventive drug therapy, despite being diagnosed in a hospital setting and despite the known substantial risk of subsequent CV events in PAD.
Compared with patients surviving MI, PAD patients have a significantly higher 1-year mortality risk (21.1% vs 13.2%) and show a comparable CV risk (16.6% vs 18.3%). 15 The present data from a clinical practice setting also indicate that patients with incident PAD might have Table I . Description of analysis population at baseline a higher CV risk than previously reported. In addition, the patients studied were considerably older and demonstrated a higher CV disease burden than is commonly observed in randomized controlled trials and quality registers. 4, 12 In our study, we have identified a unique population, patients with their first PAD diagnosis in a specialist setting at a nationwide level. This population of patients has previously not been well described and clearly shows that for many PAD patients, the first clinical manifestation of atherosclerotic disease is limb symptoms. Even the primary PAD population had a doubled CV event rate compared with the PAD population included in the REduction of Atherothrombosis for Continued Health (REACH) registry. 4 In accordance with observations in the present study, a smaller proportion of patients with PAD than with PAD and other CV diseases, also in the REACH registry, received antiplatelet therapy and statins. Having an additional history of stroke before the PAD diagnosis was associated with a markedly increased risk of death and CV events (1-year CV event rate of 30% and 25%, respectively). These findings are in congruence with the Second Manifestations of Arterial Disease (SMART) study, in which patients with recent IS and PAD had a doubled risk of future CV events compared with coronary artery disease patents. 16 The PAD þ IS population in our study was slightly older, but on the other hand, the comorbidity status was somewhat milder with regard to diabetes mellitus, hypertension, heart failure, chronic obstructive pulmonary disease, and renal failure compared with the PAD þ CHD population. Compared with patients with PAD þ IS, those with PAD þ CHD were more often treated with secondary preventive drug therapy. The high CV event rates among individuals with PAD þ IS compared with those with PAD þ CHD may be due to an effect of less aggressive treatment of risk factors in terms of medication (Fig 1) , but it may also be attributable to impaired ability of preventive physical activity rather than a higher burden of risk factors. Polyvascular disease is a particular challenge in patients with atherosclerosis and is possibly underdiagnosed. In our incident PAD population, 40% of individuals were already affected by atherosclerotic disease in other vascular beds. Mostaza et al found evidence of subclinical PAD in >30% of individuals with CHD and IS. 17 Measurement of ankle-brachial index may be considered among broader CV populations to identify individuals at high risk warranting a more intensive treatment. Despite PAD's being diagnosed in a hospital setting, patients with PAD were not well managed regarding guideline-recommended secondary preventive drug therapy. Our findings are consistent with a contemporary population-based study from Canada reporting that a similar proportion of patients received statin treatment (w60%), but there was a better adherence to ACE inhibitors (w70%). 12 When examining the initiation of these drugs in relation to timing of the PAD diagnosis (Fig 1) , it was unclear whether it was the physicians in the hospital or in primary care who initiated the therapy, as the proportion of patients receiving therapy increased up to 3 months after the PAD diagnosis. The uncertainty about responsibilities for drug treatment initiation between specialist and primary care is unfortunate and may explain the low percentage of primary PAD patients receiving adequate secondary medical treatment. It is likely that quality of care of these patients can be improved by adopting processes from other areas. This is a different drug initiation pattern compared with, for example, patients with MI, for which it is the hospital specialists who initiate treatment, showing a decline in the proportion of patients receiving treatment after discharge. 15 The long-term outcome and secondary drug therapy treatment pattern of patients with prevalent MI in Sweden are well described and managed, with acetylsalicylic acid, ACE inhibitors/angiotensin receptor blockers, and statins used by 91%, 78%, and 78% of patients at 1 year after MI, respectively. 15 Corresponding figures for patients with PAD 1 year after diagnosis in this study were 60%, 40%, and 50%, respectively. A recent registry-based study in Denmark, having a similar health care system as Sweden, showed equally poor results for individuals with PAD. 5 More than half of patients did not receive any antiplatelet therapy by 3 months after diagnosis, and nearly two-thirds did not receive statins. 5 A slightly higher adherence rate was demonstrated for patients undergoing lower limb revascularization in Sweden 1 year postoperatively, with use of acetylsalicylic acid, ACE inhibitors, and statins of 75%, 40%, and 50%, respectively. 8 In addition to reducing CV risk, treatment aims for PAD include the management of limb symptoms. PAD is associated with functional limitations or rest pain and skin ulcers, which can lead to gangrene. In recent studies, it has been shown that health-related quality of life was more markedly reduced in patients with PAD, irrespective of PAD disease stage, than for those with coronary artery disease. [18] [19] [20] Our study showed that relatively few patients were offered revascularization procedures, with fewer than one in four patients revascularized within the first 12 months after PAD diagnosis. This study includes data from all patients in Sweden receiving a PAD diagnosis in a hospital setting. This means a lower likelihood of selection bias compared with other CV health registers including only consenting patients by active recruitment. As a registry study, the validity of our findings depends on the quality and completeness of ICD-10 codes for morbidity data recorded in the registry, and therefore the possibility of coding errors cannot be excluded. However, we included only patients with ICD-10 codes I70.0, I70.2, and 173.9B for PAD, and previous validation of the Swedish NPR database has demonstrated that coding is correct in >98% of entries. 13 Our study included only diagnoses made in a hospital setting, and it cannot be ruled out that some patients will have had PAD or CHD (eg, stable angina pectoris) diagnosed in a primary care setting before hospital diagnosis of PAD recorded in the Swedish NPR. Furthermore, we did not have access to data on important clinical risk factors (eg, tobacco use, serum lipids, body mass index, and blood pressure). Another limitation of the study is that the included ICD-10 codes do not allow a delineation of the symptomatic status of the PAD patients or discrimination of patients with intermittent claudication from patients with clinical limb ischemia.
CONCLUSIONS
In this nationwide cohort study including patients diagnosed with PAD in a hospital setting, more than one in five will die within 1 year and one in six will experience a major CV event within 1 year. Patients with symptomatic PAD as the initial manifestation of atherosclerotic disease are at high risk: one in six patients will die within 1 year and one in eight will experience a major CV event within 1 year. A history of IS markedly increased the risk. Despite PAD's being diagnosed in a hospital setting and patients' being at high risk of CV events, many patients with PAD did not receive secondary preventive drug therapy. Our findings suggest that risk prevention should be the key strategy in the management of patients with PAD: positive lifestyle changes should be encouraged, and patients with PAD should be prescribed secondary preventive drug therapy with antiplatelet therapy and statins at hospital discharge. Ideally, to reduce long-term CV and limb events, PAD patients should be offered participation in guideline-recommended risk reduction programs. 21 Preferably, the discharge summary sent to the primary care physician from the hospital setting should include specialist guidance on future target doses to secure adequate follow-up for these high-risk patients.
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